Preview

Медицинский алфавит

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Терапия тазовой боли, связанной с эндометриозом: преодоление неразрешенных проблем

https://doi.org/10.33667/2078-5631-2020-26-38-44

Полный текст:

Аннотация

Обзор посвящен проблеме выбора оптимальной тактики ведения пациентов с эндометриоз-ассоциированной тазовой болью в контексте обеспечения качества жизни и сохранения фертильности. Диагностика эндометриоза с помощью прямой визуализации в последнее время подвергается критике ввиду неизбежно возникающей отсрочки в установлении окончательного диагноза. Операция не должна быть выбором для всех пациенток с подозрением на эндометриоз, и вопрос эмпирической гормональной терапии актуален, как и задача назначения длительной терапии с целью улучшения качества жизни. Современные представления о патогенезе эндометриоза, происхождении тазовой боли и фармакологических свойствах гормональных лекарственных средств, изложенные в статье, позволяют выстроить концепцию долговременного ведения женщин с тазовой болью, доказанно или предположительно ассоциированной с эндометриозом.

Об авторе

И. В. Кузнецова
НОЧУ ДПО «Высшая медицинская школа»; МЦ «Московская академическая клиника ЭКО»
Россия

д.м.н., проф., рук. направления «гинекологическая эндокринология»; директор по научной работе

Москва



Список литературы

1. Hickey M, Ballard K, Farquhar C. Endometriosis. BMJ. 2014; 348: g1752. [PubMed: 24647161]

2. Cousins FL, O DF, Gargett CE. Endometrial stem/ progenitor cells and their role in the pathogenesis of endometriosis. Best Pract Res Clin Obstet Gynaecol. 2018; 50: 27–38. DOI: 10.1016/j.bpobgyn.2018.01.011.

3. Méar L, Herr M, Fauconnier A, Pineau C, Vialard F. Polymorphisms and endometriosis: a systematic review and meta-analyses. Hum Reprod Update. 2020; 26 (1): 73–102. DOI: 10.1093/humupd/dmz034.

4. Bruner-Tran KL, Resuehr D, Ding T, JA L, Osteen K. The Role of Endocrine Disruptors in the Epigenetics of Reproductive Disease and Dysfunction: Potential Relevance to Humans. Current Obstet Gynecol Rep. 2012; 1: 116–123.

5. Bruner-Tran KL, Mokshagundam S, Herington JL, Ding T, Osteen KG. Rodent Models of Experimental Endometriosis: Identifying Mechanisms of Disease and Therapeutic Targets. Curr Womens Health Rev. 2018; 14 (2): 173–188. DOI: 10.2174/1573404813666170921162041.

6. Herington JL, Bruner-Tran KL, Lucas JA, Osteen KG. Immune interactions in endometriosis. Expert Rev Clin Immunol. 2011; 7: 611–626.

7. Оразов М. Р., Духин А. О., Носенко Е. Н. Роль пролиферации и апоптоза при аденомиозе, сопровождающемся синдромом хронической тазовой боли. Доктор.Ру. 2016; 3 (120): 5–8.

8. Hu X, Zhou Y, Feng Q, Wang R, Su L, Long J, Wei B. Association of endometriosis risk and genetic polymorphisms involving biosynthesis of sex steroids and their receptors: an updating meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2012; 164 (1): 1–9. DOI: 10.1016/j.ejogrb.2012.05.008.

9. Shao R, Cao S, Wang X, Feng Y, Billig H. The elusive and controversial roles of estrogen and progesterone receptors in human endometriosis. Am J Transl Res 2014; 6 (2): 104–113.

10. Campbell L, Emmerson E, Williams H, Saville CR, Krust A, Chambon P, Mace KA, Hardman MJ. Estrogen receptor-alpha promotes alternative macrophage activation during cutaneous repair. J Invest Dermatol. 2014; 134 (9): 2447–2457.

11. Heublein S, Vrekoussis T, Kuhn C, Friese K, Makrigiannakis A, Mayr D, Lenhard M, Jeschke U. Inducers of G-protein coupled estrogen receptor (GPER) in endometriosis: potential implications for macrophages and follicle maturation. J Reprod Immunol. 2013; 97 (1): 95–103.

12. Okamoto M, Suzuki T, Mizukami Y, Ikeda T. The membrane-type estrogen receptor G-protein-coupled estrogen receptor suppresses lipopolysaccharide-induced interleukin 6 via inhibition of nuclear factor-kappa B pathway in murine macrophage cells. Anim Sci J. 2017; 88 (11): 1870–1879.

13. Bulun SE, Cheng Y-H, Pavone ME, et al. 17β-Hydroxysteroid Dehydrogenase-2 Deficiency and Progesterone Resistance in Endometriosis. Semin Reprod Med. 2010; 28 (1): 44–50.

14. Szczepańska M, Wirstlein P, Skrzypczak J, Jagodziński PP. Expression of HOXA11 in the mid-luteal endometrium from women with endometriosis-associated infertility. Reprod Biol Endocrinol. 2012; 10 (1): 1.

15. Liang Y, Yao S. Potential role of estrogen in maintaining the imbalanced sympathetic and sensory innervation in endometriosis. Mol Cell Endocrinol. 2016; 424: 42–49. DOI: 10.1016/j.mce.2016.01.012.

16. Barcena DAM, Oldeweme J, Arnold J, Schneider A, Mechsner S. Remodeling of estrogen-dependent sympathetic nerve fibers seems to be disturbed in adenomyosis. Fertil Steril. 2013; 100 (3): 801–809.

17. Monica BM, Smith PG. Estrogen and female reproductive tract innervation: cellular and molecular mechanisms of autonomic neuroplasticity. Auton Neurosci. 2015; 187: 1–17.

18. Greaves E, Collins F, Esnal-Zufiaurre A, Giakoumelou S, Horne AW, Saunders PT. Estrogen receptor (ER) agonists differentially regulate neuroangiogenesis in peritoneal endometriosis via the repellent factor SLIT3. Endocrinology. 2014; 155 (10): 4015–4026.

19. Rowan MP, Berg KA, Roberts JL, Hargreaves KM, Clarke WP. Activation of estrogen receptor alpha enhances bradykinin signaling in peripheral sensory neurons of female rats. J Pharmacol Exp Ther. 2014; 349 (3): 526–532.

20. Altun I, Kurutas EB. G protein-coupled estrogen receptor levels after peripheral nerve injury in an experimental rat model. World Neurosurg. 2015; 84 (6): 1903–196.

21. Zhang X, Lu B, Huang X, Xu H, Zhou C, Lin J. Innervation of endometrium and myometrium in women with painful adenomyosis and uterine fibroids. Fertil Steril. 2010; 94 (2): 730–737. DOI: 10.1016/j.fertnstert.2009.03.026.

22. Miller EJ, Fraser IS. The importance of pelvic nerve fibers in endometriosis. Womens Health (Lond). 2015; 11 (5): 611–618.

23. Yan D, Liu X, Guo SW. Nerve fibers and endometriotic lesions: partners in crime in inflicting pains in women with endometriosis. Eur J Obstet Gynecol Reprod Biol. 2017; 209: 14–24. DOI: 10.1016/j.ejogrb.2016.06.017.

24. McKinnon B, Bersinger NA, Wotzkow C, Mueller MD. Endometriosis-associated nerve fibers, peritoneal fluid cytokine concentrations, and pain in endometriotic lesions from different locations. Fertil Steril. 2012; 97 (2): 373–380. DOI: 10.1016/j.fertnstert.2011.11.011.

25. Wang G, Tokushige N, Fraser IS. Nerve fibers and menstrual cycle in peritoneal endometriosis. Fertil Steril. 2011; 95 (8): 2772–2274. DOI: 10.1016/j.fertnstert.2011.01.150.

26. Wei Y, Liang Y, Lin H, Dai Y, Yao S. Autonomic nervous system and inflammation interaction in endometriosis-associated pain. J Neuroinflammation. 2020; 17 (1): 80. DOI: 10.1186/s12974–020–01752–1.

27. Liang Y, Xie H, Wu J, Liu D, Yao S. Villainous role of estrogen in macrophage-nerve interaction in endometriosis. Reprod Biol Endocrinol. 2018 Dec 5; 16 (1): 122. DOI: 10.1186/s12958–018–0441-z.

28. Forster R, Sarginson A, Velichkova A, Hogg C, Dorning A, Horne AW, Saunders PTK, Greaves E. Macrophage-derived insulin-like growth factor-1 is a key neurotrophic and nerve-sensitizing factor in pain associated with endometriosis. FASEB J. 2019 Oct; 33 (10): 11210–11222. DOI: 10.1096/fj.201900797R.

29. Nnoaham KE, Hummelshoj L, Webster P, et al. Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries. Fertil Steril. 2011; 96 (2): 366–373.

30. Hansen KE, Kesmodel US, Baldursson EB, Kold M, Forman A. Visceral syndrome in endometriosis patients. Eur J Obstet Gynecol Reprod Biol 2014; 179: 198–203.

31. Facchin F, Barbara G, Dridi D, et al. Mental health in women with endometriosis: searching for predictors of psychological distress. Hum Reprod 2017; 32 (9): 1855–1861.

32. Zarbo C, Brugnera A, Dessì V, et al. Cognitive and Personality Factors Implicated in Pain Experience in Women with Endometriosis: A Mixed Method Study. Clin J Pain 2019; 35 (12): 948–957.

33. Maggiore LRU, Bizzarri N, Scala C, Tafi E, Siesto G, Alessandri F, Ferrero S. Symptomatic endometriosis of the posterior cul-de-sac is associated with impaired sleep quality, excessive daytime sleepiness and insomnia: a case-control study. Eur J Obstet Gynecol Reprod Biol. 2017; 209: 39–43.

34. Simoens S, Dunselman G, Dirksen C, et al. The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centers. Hum Reprod 2012; 27: 1292–1299.

35. Kundu S, Wildgrube J, Schippert C, Hillemanns P, Brandes I. Supporting and Inhibiting Factors When Coping with Endometriosis from the Patients′ Perspective. Geburtshilfe Frauenheilkd. 2015; 75 (5): 462–469.

36. Johnson NP, Hummelshoj L. Consensus on current management of endometriosis. Hum Reprod. 2013; 28 (6): 1552–1568.

37. Mowers EL, Lim CS, Skinner B, Mahnert N, Kamdar N, Morgan, DM, As-Sanie S. Prevalence of Endometriosis During Abdominal or Laparoscopic Hysterectomy for Chronic Pelvic Pain. Obstet Gynecol 2016; 127 (6): 1045–1053.

38. Streuli I, de Ziegler D, Gayet V, Santulli P, Bijaoui G, de Mouzon J, Chapron C. In women with endometriosis anti-Mullerian hormone levels are decreased only in those with previous endometrioma surgery. Hum Reprod. 2012; 27: 3294–3303.

39. Dunselman GAJ, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod 2014; 29 (3): 400–412.

40. Durham JD, Machan L. Pelvic congestion syndrome. Semin Intervent Radiol. 2013; 30 (4): 372–380. DOI: 10.1055/s-0033–1359731.

41. Speer LM, Mushkbar S, Erbele T. Chronic Pelvic Pain in Women. Am Fam Physician. 2016; 93 (5): 380–387. PMID: 26926975.

42. Johnson NP, Hummelshoj L. World Endometriosis Society Montpellier Consortium: Consensus on current management of endometriosis. Hum Reprod 2013; 28 (6): 1552–1568.

43. Hong IS, Klausen C, Cheung AP, Leung PC. Gonadotropin-releasing hormone-I or II interacts with IGF-I/ Akt but not connexin 43 in human granulosa cell apoptosis. J Clin Endocrin Metab 2012; 97 (2): 525–534.

44. Nigrinakis K, Bersinger NA, McKinnon B, et al. Regression of the inflammatory microenvironment of the peritoneal cavity in women with endometriosis by GnRHa treatment. Eur J Obstet Gynecol Reprod Biol 2013; 170 (2): 550–554.

45. Muramatsu T. Structure and function of midkine as a basis of its pharmacological effects. Br J Pharmacol 2014; 171 (4): 814–826.

46. Huang F, Wang H, Zou Y, Liu Q, Cao J, Yin. Effect of GnRH-II on the ESC proliferation, apoptosis and VEGF secretion in patients with endometriosis in vitro. Int J Clin Exp Pathol. 2013; 6 (11): 2487–2496.

47. Alshehre SM, Duffy S, Jones G, Ledger WL, Metwally M. A prospective, single-centre, single-arm, open label study of the longterm use of a gonadotropin releasing hormone agonist (Triptorelin SR, 11.25 mg) in combination with Tibolone add-back therapy in the management of chronic cyclical pelvic pain. Reprod Biol Endocrinol. 2020; 18 (1): 28. DOI: 10.1186/s12958–020–00586-z.

48. Schindler AE. Dienogest in long-term treatment of endometriosis. Int J Womens Health. 2011; 3: 175–184. DOI: 10.2147/IJWH.S5633.

49. Bedaiwy MA, Allaire C, Alfaraj S: Long-term medical management of endometriosis with dienogest and with a gonadotropin-releasing hormone agonist and add-back hormone therapy. Fertil Steril. 2017; 107 (3): 537–548.

50. Grandi G, Mueller M, Bersinger NA, Cagnacci A, Volpe A, McKinnon B. Does dienogest influence the inflammatory response of endometriotic cells? A systematic review. Inflamm Res. 2016; 65 (3): 183–192. DOI: 10.1007/s00011–015–0909–7.

51. Shimizu Y, Mita S, Takeuchi T, Notsu T, Mizuguchi K, Kyo S. Dienogest, a synthetic progestin, inhibits prostaglandin E2 production and aromatase expression by human endometrial epithelial cells in a spheroid culture system. Steroids. 2011; 76 (1–2): 60–7. DOI: 10.1016/j.steroids.2010.08.010.

52. Yamanaka K, Xu B, Suganuma I, et al. Dienogest inhibits aromatase and cyclooxygenase-2 expression and prostaglandin E2 production in human endometriotic stromal cells in spheroid culture. Fertil Steril. 2012; 97 (2): 477–482.

53. Mita S, Shimizu Y, Sato A, Notsu T, Imada K, Kyo S. Dienogest inhibits nerve growth factor expression induced by tumor necrosis factor-α or interleukin-1β. Fertil Steril. 2014; 101 (2): 595–601.

54. Caruso S, Iraci M, Cianci S, Casella E, Fava V, Cianci A. Quality of life and sexual function of women affected by endometriosis-associated pelvic pain when treated with dienogest. J Endocrinol Invest. 2015; 38 (11): 1211–8. DOI: 10.1007/s40618–015–0383–7.

55. Jeng CJ, Chuang L, Shen J. A comparison of progestogens or oral contraceptives and gonadotropin-releasing hormone agonists for the treatment of endometriosis: a systematic review. Expert Opin Pharmacother. 2014; 15 (6): 767–773.

56. Andres Mde P, Lopes LA, Baracat EC, Podgaec S. Dienogest in the treatment of endometriosis: systematic review. Arch Gynecol Obstet. 2015; 292 (3): 523–529. DOI: 10.1007/s00404–015–3681–6.

57. Тихонова Е. С. Медицинские и социальные аспекты генитального эндометриоза: Автореф. дис. … канд. мед. наук. М., 2013; 26 с.

58. Leonardo-Pinto JP, Benetti-Pinto CL, Cursino K, Yela DA. Dienogest and deep infiltrating endometriosis: The remission of symptoms is not related to endometriosis nodule remission. Eur J Obstet Gynecol Reprod Biol. 2017; 211: 108–111. DOI: 10.1016/j.ejogrb.2017.02.015.

59. Koga K, Takamura M, Fujii T, Osuga Y. Prevention of the recurrence of symptom and lesions after conservative surgery for endometriosis. Fertil Steril. 2015; 104 (4): 793–801. DOI: 10.1016/j.fertnstert.2015.08.026.

60. Bedaiwy M, Allaire C, Yong P, et al. Medical Management of Endometriosis in Patients with Chronic Pelvic Pain. Semin Reprod Med 2017; 35 (1): 38–53.

61. Brown J, Crawford TJ, Datta S, Prentice A. Oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev. 2018; 5 (5): CD001019. DOI: 10.1002/14651858.CD001019.pub3.

62. Caruso S, Iraci M, Cianci S, Fava V, Casella E, Cianci A. Comparative, open-label prospective study on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain on 2 mg dienogest/30 µg ethinyl estradiol continuous or 21/7 regimen oral contraceptive. J Endocrinol Invest. 2016; 39(8): 923–931.

63. Schindler AE. Non-contraceptive benefits of hormonal contraception. Minerva Ginecol 2010; 62: 319–329.

64. Wiegratz I, Stahlberg S, Manthey T, et al. Effect of extended-cycle regimen with an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on bleeding patterns, safety, acceptance and contraceptive efficacy. Contraception. 2011; 84 (2): 133–143.

65. Vercellini P, Barbara G, Somigliana E, Bianchi S, Abbiati A, Fedele L. Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis. Fertil Steril 2010; 93: 2150–2161.

66. Dmitrovic R, Kunselman AR, Legro RS. Continuous Compared with Cuclic Oral Contraceptives for the Treatment of Primary Dysmenorrhea: A Randomized Controlled Trial. Obstet Gynecol 2012; 119 (6): 1143–1150.

67. Practice Committee of the American Society for Reproductive Medicine: Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil Steril 2014; 101 (4): 927–935.

68. Ulrich U, Buchweitz O, Greb R, et al, for the German and Austrian Societies for Obstetrics and Gynecology. National German Guideline (S2k): Guideline for the Diagnosis and Treatment of Endometriosis: Long Version – AWMF Registry No. 015–045. Geburtshilfe Frauenheilkd 2014; 74 (12): 1104–1118.

69. Royal College of Obstetricians and Gynecologists, Faculty of Sexual & Reproductive Health Care. Contraception for Women Aged over 40 years; 2010 www.fsrh.org/pages/clinical guidance.asp

70. Cibula D, Gompel A, Mueck AO, La Vecchia C, Hannaford PC, Skouby SO, Zikan M, Dusek L. Hormonal contraception and risk of cancer. Hum Reprod Update 2010; 16: 631–650.

71. Mueck AO, Seeger H, Ruan X. Oral contraception and risk of endometrial cancer. J Contracept 2011; 2: 127–136.

72. Reid RL, Westhoff C, Mansour D, et al. Oral contraceptives and venous thromboembolism. Consensus opinion from an International Workshop held in Berlin, Germany in December 2009. J Fam Plann Reprod Health Care 2010; 36: 117–122.

73. de Bastos M, Stegeman BH, Rosendaal FR, Van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM. Combined oral contraceptives: venous thrombosis (review). Cochrane Library 2014; (3). www.thecochranelibrary.com.

74. Mantha S, Karp R, Raghavan V, Terrin N, Bauer KA, Zwicker JI. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ 2012; 345: e4944. DOI.org/10.1136/bmj.e4944.


Для цитирования:


Кузнецова И.В. Терапия тазовой боли, связанной с эндометриозом: преодоление неразрешенных проблем. Медицинский алфавит. 2020;(26):38-44. https://doi.org/10.33667/2078-5631-2020-26-38-44

For citation:


Kuznetsova I.V. Therapy for pelvic pain associated with endometriosis: overcoming unresolved issues. Medical alphabet. 2020;(26):38-44. (In Russ.) https://doi.org/10.33667/2078-5631-2020-26-38-44

Просмотров: 35


ISSN 2078-5631 (Print)